Polarized immune responses modulated by layered double hydroxides nanoparticle conjugated with CpG

Biomaterials

Volumn 35, Issue 35, 2014, Pages 9508-9516

  Yan, Shiyu ^a   Rolfe, Barbara E ^a   Zhang, Bing ^b   Mohammed, Yousuf H ^a   Gu, Wenyi ^a   Xu, Zhi P ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b DEPARTMENT OF AGRICULTURE AND FISHERIES   (Australia)

Author keywords

Immunity polarization; Layered double hydroxide nanomaterial; Nanoadjuvant; Th1 and Th2 immune responses; Toll like receptor (TLR) ligand CpG

Indexed keywords

LIGANDS; MOBILE SECURITY; NANOPARTICLES; NANOSTRUCTURED MATERIALS; TUMORS; VACCINES;

ANTIBODY RESPONSE; CHEMICAL COMPOSITIONS; IMMUNE RESPONSE; LAYERED DOUBLE HYDROXIDES; MG-AL LAYERED DOUBLE HYDROXIDE; NANOADJUVANT; NANOMATERIAL; TOLL-LIKE RECEPTORS;

IMMUNE SYSTEM;

ALUMINUM POTASSIUM SULFATE; CPG OLIGODEOXYNUCLEOTIDE; HYDROXIDE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; NANOMATERIAL; NANOPARTICLE; OVALBUMIN; TOLL LIKE RECEPTOR; ALUMINUM SULFATE; HYDROXIDE ION; IMMUNOGLOBULIN G;

ANIMAL CELL; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CANCER INHIBITION; CONJUGATION; CONTROLLED STUDY; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; ANIMAL; ANTIBODY PRODUCTION; C57BL MOUSE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHEMISTRY; COMPARATIVE STUDY; CPG ISLAND; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG EFFECTS; FEMALE; IMMUNOLOGY; METABOLISM; PHYSICAL CHEMISTRY; TUMOR CELL LINE;

MUS;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODY FORMATION; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CPG ISLANDS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FEMALE; HYDROXIDES; IMMUNITY, CELLULAR; IMMUNIZATION; IMMUNOGLOBULIN G; MICE; MICE, INBRED C57BL; NANOPARTICLES; OVALBUMIN; PHYSICOCHEMICAL PHENOMENA;

EID: 84926193459     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.07.055     Document Type: Article

References (54)

1. Ochoa-Repáraz J., García B., Solano C., Lasa I., Irache J.M., Gamazo C. Protective ability of subcellular extracts from Salmonella Enteritidis and from a rough isogenic mutant against salmonellosis in mice. Vaccine 2005, 23:1491-1501.
2. Thomas D.P., Viudes A., Monteagudo C., Lazzell A.L., Saville S.P., López-Ribot J.L. Aproteomic-based approach for the identification of Candida albicans protein components present in a subunit vaccine that protects against disseminated candidiasis. Proteomics 2006, 6:6033-6041.
3. Winther M.D., Dougan G. The impact of new technologies on vaccine development. Biotechnol Genet Eng Rev 1984, 2:1-39.
4. Gupta R.K., Siber G.R. Adjuvants for human vaccines-current status, problems and future prospects. Vaccine 1995, 13:1263-1276.
5. Robinson D.S., Hamid Q., Ying S., Tsicopoulos A., Barkans J., Bentley A.M., et al. Predominant Th2-like bronchoalveolar T-lymphocyte population in atopic asthma. NEngl J Med 1992, 326:298-304.
6. Mastelic B., Ahmed S., Egan W.M., Del Giudice G., Golding H., Gust I., et al. Mode of action of adjuvants: implications for vaccine safety and design. Biologicals 2010, 38:594-601.
7. Petrovsky N., Aguilar J.C. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004, 82:488-496.
8. Dabbagh K., Lewis D.B. Toll-like receptors and T-helper-1/T-helper-2 responses. Curr Opin Infect Dis 2003, 16:199-204.
9. Romagnani S. The role of lymphocytes in allergic disease. JAllergy Clin Immunol 2000, 105:399-408.
10. Romagnani P., Annunziato F., Piccinni M.-P., Maggi E., Romagnani S. Cytokines and chemokines in T lymphopoiesis and T-cell effector function. Immunol Today 2000, 21:416-418.
11. Rotmagnani S. The Th1/Th2 paradigm and allergic disorders. Allergy 1998, 53:12-15.
12. Seo S., Han H., Noh K., Kim T., Son S. Chitosan hydrogel containing GMCSF and a cancer drug exerts synergistic anti-tumor effects via the induction of CD8+ T cell-mediated anti-tumor immunity. Clin Exp Metastasis 2009, 26:179-187.
13. Bevan M.J. Antigen presentation to cytotoxic T lymphocytes invivo. JExp Med 1995, 182:639-641.
14. Xu Z.P., Zeng Q.H., Lu G.Q., Yu A.B. Inorganic nanoparticles as carriers for efficient cellular delivery. Chem Eng Sci 2006, 61:1027-1040.
15. Li L., Gu W., Chen J., Chen W., Xu Z.P. Co-delivery of siRNAs and anti-cancer drugs using layered double hydroxide nanoparticles. Biomaterials 2014, 35:3331-3339.
16. Kwak S.-Y., Jeong Y.-J., Park J.-S., Choy J.-H. Bio-LDH nanohybrid for gene therapy. Solid state Ionics 2002, 151:229-234.
17. Xu Z.P., Walker T.L., Liu K.L., Cooper H.M., Lu G.Q., Bartlett P.F. Layered double hydroxide nanoparticles as cellular delivery vectors of supercoiled plasmid DNA. Int J Nanomedicine 2007, 2:163-174.
18. Wong Y., Cooper H.M., Zhang K., Chen M., Bartlett P., Xu Z.P. Efficiency of layered double hydroxide nanoparticle-mediated delivery of siRNA is determined by nucleotide sequence. JColloid Interface Sci 2012, 369:453-459.
19. Kim J.Y., Choi S.J., Oh J.M., Park T., Choy J.H. Anticancer drug-inorganic nanohybrid and its cellular interaction. JNanosci Nanotechnol 2007, 7:3700-3705.
20. Nalawade P., Aware B., Kadam V.J., Hirlekar R.S. Layered double hydroxides: a review. JSci Ind Res 2009, 68:267-272.
21. Jin L., He D., Li Z., Wei M. Protein adsorption on gold nanoparticles supported by a layered double hydroxide. Mater Lett 2012, 77:67-70.
22. Xu Z.P., Jin Y., Liu S., Hao Z.P., Lu G.Q. Surface charging of layered double hydroxides during dynamic interactions of anions at the interfaces. JColloid Interface Sci 2008, 326:522-529.
23. Szilagyi I., Trefalt G., Tiraferri A., Maroni P., Borkovec M. Polyelectrolyte adsorption, interparticle forces, and colloidal aggregation. Soft matter 2014, 10:2479-2502.
24. Gu Z., Rolfe B.E., Thomas A.C., Campbell J.H., Lu G.Q., Xu Z.P. Cellular trafficking of low molecular weight heparin incorporated in layered double hydroxide nanoparticles in rat vascular smooth muscle cells. Biomaterials 2011, 32:7234-7240.
25. Xu Z.P., Niebert M., Porazik K., Walker T.L., Cooper H.M., Middelberg A.P., et al. Subcellular compartment targeting of layered double hydroxide nanoparticles. JControl Release 2008, 130:86-94.
26. Kriven W.M., Kwak S.-Y., Wallig M.A., Choy J.-H. Bio-resorbable nanoceramics for gene and drug delivery. MRS Bull 2004, 29:33-37.
27. Kawai T., Akira S. TLR signaling. Cell Death Differ 2006, 13:816-825.
28. Takeda K., Akira S. Toll-like receptors in innate immunity. Int Immunol 2005, 17:1-14.
29. Warren T.L., Dahle C.E., Weiner G.J. CpG oligodeoxynucleotides enhance monoclonal antibody therapy of a murine lymphoma. Clin Lymphoma 2000, 1:57-61.
30. Weiner G.J., Liu H.M., Wooldridge J.E., Dahle C.E., Krieg A.M. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci U S A 1997, 94:10833-10837.
31. Sands H., Gorey-Feret L.J., Cocuzza A.J., Hobbs F.W., Chidester D., Trainor G.L. Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol Pharmacol 1994, 45:932-943.
32. Malyala P., O'Hagan D.T., Singh M. Enhancing the therapeutic efficacy of CpG oligonucleotides using biodegradable microparticles. Adv Drug Deliv Rev 2009, 61:218-225.
33. Ozkan M. Quantum dots and other nanoparticles: what can they offer to drug discovery?. Drug Discov Today 2004, 9:1065-1071.
34. Barbé C., Bartlett J., Kong L., Finnie K., Lin H.Q., Larkin M., et al. Silica particles: a novel drug-delivery system. Adv Mater 2004, 16:1959-1966.
35. Bauer L.A., Birenbaum N.S., Meyer G.J. Biological applications of high aspect ratio nanoparticles. JMater Chem 2004, 14:517-526.
36. Krishnamachari Y., Salem A.K. Innovative strategies for co-delivering antigens and CpG oligonucleotides. Adv Drug Deliv Rev 2009, 61:205-217.
37. Williams G.R., Fierens K., Preston S.G., Lunn D., Rysnik O., De Prijck S., et al. Immunity induced by a broad class of inorganic crystalline materials is directly controlled by their chemistry. JExp Med 2014, 211:1019-1025.
38. Heit A., Schmitz F., Haas T., Busch D.H., Wagner H. Antigen co-encapsulated with adjuvants efficiently drive protective T cell immunity. Eur J Immunol 2007, 37:2063-2074.
39. Xu Z.P., Stevenson G.S., Lu C.Q., Lu G.Q., Bartlett P.F., Gray P.P. Stable suspension of layered double hydroxide nanoparticles in aqueous solution. JAm Chem Soc 2006, 128:36-37.
40. Xu Z.P., Stevenson G., Lu C.Q., Lu G.Q. Dispersion and size control of layered double hydroxide nanoparticles in aqueous solutions. JPhys Chem B 2006, 110:16923-16929.
41. Garlapati S., Eng N.F., Wilson H.L., Buchanan R., Mutwiri G.K., Babiuk L.A., et al. PCPP (poly[di(carboxylatophenoxy)-phosphazene]) microparticles co-encapsulating ovalbumin and CpG oligo-deoxynucleotides are potent enhancers of antigen specific Th1 immune responses in mice. Vaccine 2010, 28:8306-8314.
42. Zhang X.Q., Dahle C.E., Baman N.K., Rich N., Weiner G.J., Salem A.K. Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles. JImmunother 2007, 30:469-478.
43. San Roman B., Irache J.M., Gomez S., Tsapis N., Gamazo C., Espuelas M.S. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology. Eur J Pharm Biopharm 2008, 70:98-108.
44. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
45. Nakayama H., Wada N., Tsuhako M. Intercalation of amino acids and peptides into Mg-Al layered double hydroxide by reconstruction method. Int J Pharm 2004, 269:469-478.
46. Ladewig K., Niebert M., Xu Z.P., Gray P.P., Lu G.Q. Efficient siRNA delivery to mammalian cells using layered double hydroxide nanoparticles. Biomaterials 2010, 31:1821-1829.
47. Wong Y., Markham K., Xu Z.P., Chen M., Max Lu G.Q., Bartlett P.F., et al. Efficient delivery of siRNA to cortical neurons using layered double hydroxide nanoparticles. Biomaterials 2010, 31:8770-8779.
48. Oh J.M., Choi S.J., Lee G.E., Kim J.E., Choy J.H. Inorganic metal hydroxide nanoparticles for targeted cellular uptake through clathrin-mediated endocytosis. Chem Asian J 2009, 4:67-73.
49. Choi S.J., Choy J.H. Layered double hydroxide nanoparticles as target-specific delivery carriers: uptake mechanism and toxicity. Nanomedicine (Lond) 2011, 6:803-814.
50. Ladewig K., Niebert M., Xu Z.P., Gray P.P., Lu G.Q. Controlled preparation of layered double hydroxide nanoparticles and their application as gene delivery vehicles. Appl Clay Sci 2010, 48:280-289.
51. Cascio P., Hilton C., Kisselev A.F., Rock K.L., Goldberg A.L. 26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide. EMBO J 2001, 20:2357-2366.
52. Bourquin C., Anz D., Zwiorek K., Lanz A.L., Fuchs S., Weigel S., et al. Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity. JImmunol 2008, 181:2990-2998.
53. Joseph A., Louria-Hayon I., Plis-Finarov A., Zeira E., Zakay-Rones Z., Raz E., et al. Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines. Vaccine 2002, 20:3342-3354.
54. Hamdy S., Molavi O., Ma Z., Haddadi A., Alshamsan A., Gobti Z., et al. Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity. Vaccine 2008, 26:5046-5057.